GOP embraces RFK Jr.’s MAHA at House hearing, with some dissents

Republicans cautiously waded into areas of controversy, pushing Kennedy without appearing to undermine him or the broader MAHA movement.

May 14, 2025 Check out STAT+

Sponsored By

John McDonnell/AP STAT+ | GOP embraces RFK Jr.'s MAHA at House hearing, but raises dissents from dental health to food dye reform GOP lawmakers tested the limits of how far they could push Kennedy without appearing to undermine him or his MAHA movement. By Lev Facher and Daniel Payne STAT+ | Projected number of uninsured from GOP's bill is nearing levels not seen since ACA repeal effort If that many lost coverage, that would push the total number of uninsured in the U.S. close to pre-Affordable Care Act levels, says KFF's Larry Levitt.  By John Wilkerson Drug overdose deaths fell sharply in 2024, as fentanyl cases dropped but meth spiked U.S. drug overdose deaths fell 27% in 2024, the lowest since 2019, with fentanyl cases down but methamphetamine sharply up, the CDC reports. By Lev Facher Sarah Gonzales for STAT Former FDA head Robert Califf says RFK Jr.'s vaccine rhetoric is 'doing harm' to Americans Ex-FDA chief Robert Califf says HHS Secretary Robert F. Kennedy Jr.'s vaccine stance is harming public health, warns of HHS chaos, politicization, staff exodus. By Lizzy Lawrence WHO trims top management ranks amid financial crunch The agency faces a salary gap of more than $500 million over the next two years, and will have to cut salary expenditures by 25%. By Helen Branswell Prenatal genetic therapy for SMA shows promise in a mouse study The study is a proof of concept. More work would need to be done before such an approach could be tested in human fetuses By Megan Molteni Adobe STAT+ | Eli Lilly and AstraZeneca top a consultancy's ranking of drug company R&D IDEA Pharma ranks firms on invention of new drugs and innovation, the ability to get those new drugs to market. Eli Lilly, AstraZeneca top 2025 lists. By Matthew Herper STAT+ | Opinion: How Medicaid can innovate in the DOGE era AI, innovative programs, and the integration of social and medical needs can let Medicaid better serve patients while remaining fiscally responsible. By Nate Favini, Andrey Ostrovsky, and Neil Batlivala

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser